Post-receptor IGF1 insensitivity restricted to the MAPK pathway in a Silver-Russell syndrome patient with hypomethylation at the imprinting control region on chromosome 11
Carregando...
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOSCIENTIFICA LTD
Autores
Citação
EUROPEAN JOURNAL OF ENDOCRINOLOGY, v.166, n.3, p.543-550, 2012
Resumo
Background: Hypomethylation of the paternal imprinting center region 1 (ICR1) is the most frequent molecular cause of Silver-Russell syndrome (SRS). Clinical evidence suggests that patients with this epimutation have mild IGF1 insensitivity. Objective: To assess in vitro IGF1 action in fibroblast culture from a patient with SRS and IGF1 insensitivity. Methods: Fibroblast cultures from one patient with SRS due to ICR1 demethylation and controls were established. The SRS patient has severe growth failure, elevated IGF1 level, and poor growth rate during human recombinant GH treatment. IGF1 action was assessed by cell proliferation, AKT, and p42/44-MAPK phosphorylation. Gene expression was determined by real-time PCR. Results: Despite normal IGF1R sequence and expression, fibroblast proliferation induced by IGF1 was 50% lower in SRS fibroblasts in comparison with controls. IGF1 and insulin promoted a p42/44-MAPK activation in SRS fibroblasts 40 and 36%, respectively, lower than that in control fibroblasts. On the other hand, p42/44-MAPK activation induced by EGF stimulation was only slightly reduced (75% in SRS fibroblasts in comparison with control), suggesting a general impairment in MAPK pathway with a greater impairment of the stimulation induced by insulin and IGF1 than by EGF. A PCR array analysis disclosed a defect in MAPK pathway characterized by an increase in DUSP4 and MEF2C gene expressions in patient fibroblasts. Conclusion: A post-receptor IGF1 insensitivity was characterized in one patient with SRS and ICR1 hypomethylation. Although based on one unique severely affected patient, these results raise an intriguing mechanism to explain the postnatal growth impairment observed in SRS patients that needs confirmation in larger cohorts.
Palavras-chave
Referências
- Abu-Amero S, 2008, J MED GENET, V45, P193, DOI 10.1136/jmg.2007.053017
- Abuzzahab MJ, 2003, NEW ENGL J MED, V349, P2211, DOI 10.1056/NEJMoa010107
- Bartholdi D, 2009, J MED GENET, V46, P192, DOI 10.1136/jmg.2008.061820
- Binder G, 2008, J CLIN ENDOCR METAB, V93, P1402, DOI 10.1210/jc.2007-1897
- CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
- Coelho JC, 2000, GENET MOL BIOL, V23, P269
- Coutinho DC, 2007, J CLIN ENDOCR METAB, V92, P4889, DOI 10.1210/jc.2007-1661
- Eggermann T, 2008, CLIN GENET, V73, P79, DOI 10.1111/j.1399-0004.2007.00930.x
- Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033
- FRANCIS GL, 1992, J MOL ENDOCRINOL, V8, P213
- Gicquel C, 2005, NAT GENET, V37, P1003, DOI 10.1038/ng1629
- Kotzot D, 2008, EUR J MED GENET, V51, P444, DOI 10.1016/j.ejmg.2008.06.001
- Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
- Modric T, 2001, ENDOCRINOLOGY, V142, P1958, DOI 10.1210/en.142.5.1958
- Munoz JP, 2009, BIOCHEM BIOPH RES CO, V388, P155, DOI 10.1016/j.bbrc.2009.07.147
- Netchine I, 2007, J CLIN ENDOCR METAB, V92, P3148, DOI 10.1210/jc.2007-0354
- Patterson KI, 2009, BIOCHEM J, V418, P475, DOI 10.1042/BJ20082234
- Silva EGP, 2003, HORM RES, V59, P229, DOI 10.1159/000070222
- TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3
- Turner CLS, 2010, EUR J HUM GENET, V18, P648, DOI 10.1038/ejhg.2009.246
- Waha A, 2010, CANCER RES, V70, P1689, DOI 10.1158/0008-5472.CAN-09-3218